OMEROS CORP APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
OMEROS CORP (OMER) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $2.64 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Shareholders' Equity › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2024-11-13
- OMEROS CORP apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2024-09-30 was $2.64M, a 18.36% decline year-over-year.
- OMEROS CORP apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2024-06-30 was $2.77M, a 0.11% decline year-over-year.
- OMEROS CORP apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2024-03-31 was $2.66M, a 9.99% decline year-over-year.
- OMEROS CORP apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2023-09-30 was $3.23M, a 15.84% decline year-over-year.
- OMEROS CORP apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $11.65M, a 17.21% decline from fiscal 2022.
- OMEROS CORP apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $14.07M, a 19.77% decline from fiscal 2021.
- OMEROS CORP apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2021 was $17.54M, a 18.75% increase from fiscal 2020.
- OMEROS CORP apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2020 was $14.77M, a 7.15% increase from fiscal 2019.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2024-09-30 | $2.64M 10-Q · filed 2024-11-13 | $5.41M derived: sum of 2 quarters · filed 2024-11-13 | $8.07M derived: sum of 3 quarters · filed 2024-11-13 | |
| 2024-06-30 | $2.77M 10-Q · filed 2024-11-13 | $5.43M derived: sum of 2 quarters · filed 2024-11-13 | ||
| 2024-03-31 | $2.66M 10-Q · filed 2024-11-13 | |||
| 2023-12-31 | $11.65M 10-K · filed 2024-04-01 | |||
| 2023-09-30 | $3.23M 10-Q · filed 2024-11-13 | $6.01M derived: sum of 2 quarters · filed 2024-11-13 | $8.96M derived: sum of 3 quarters · filed 2024-11-13 | |
| 2023-06-30 | $2.77M 10-Q · filed 2024-11-13 | $5.72M derived: sum of 2 quarters · filed 2024-11-13 | ||
| 2023-03-31 | $2.95M 10-Q · filed 2024-11-13 | |||
| 2022-12-31 | $14.07M 10-K · filed 2024-04-01 | |||
| 2022-09-30 | $3.84M 10-Q · filed 2023-11-09 | $6.92M derived: sum of 2 quarters · filed 2023-11-09 | $10.81M derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $3.07M 10-Q · filed 2023-11-09 | $6.96M derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | $3.89M 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $17.54M 10-K · filed 2024-04-01 | |||
| 2021-09-30 | $5.69M 10-Q · filed 2022-11-09 | $8.81M derived: sum of 2 quarters · filed 2022-11-09 | $12.08M derived: sum of 3 quarters · filed 2022-11-09 | |
| 2021-06-30 | $3.12M 10-Q · filed 2022-11-09 | $6.39M derived: sum of 2 quarters · filed 2022-11-09 | ||
| 2021-03-31 | $3.27M 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $14.77M 10-K · filed 2023-03-13 | |||
| 2020-09-30 | $3.82M 10-Q · filed 2021-11-09 | $7.65M derived: sum of 2 quarters · filed 2021-11-09 | $11.12M derived: sum of 3 quarters · filed 2021-11-09 | |
| 2020-06-30 | $3.82M 10-Q · filed 2021-11-09 | $7.30M derived: sum of 2 quarters · filed 2021-11-09 | ||
| 2020-03-31 | $3.48M 10-Q · filed 2021-11-09 | |||
| 2019-12-31 | $13.79M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $3.50M 10-Q · filed 2020-11-09 | $7.09M derived: sum of 2 quarters · filed 2020-11-09 | $10.47M derived: sum of 3 quarters · filed 2020-11-09 | |
| 2019-06-30 | $3.60M 10-Q · filed 2020-11-09 | $6.97M derived: sum of 2 quarters · filed 2020-11-09 | ||
| 2019-03-31 | $3.37M 10-Q · filed 2020-11-09 | |||
| 2018-12-31 | $11.71M 10-K · filed 2021-03-01 | |||
| 2018-09-30 | $2.93M 10-Q · filed 2019-11-12 | $5.93M derived: sum of 2 quarters · filed 2019-11-12 | $8.89M derived: sum of 3 quarters · filed 2019-11-12 | |
| 2018-06-30 | $3.00M 10-Q · filed 2019-11-12 | $5.97M derived: sum of 2 quarters · filed 2019-11-12 | ||
| 2018-03-31 | $2.97M 10-Q · filed 2019-11-12 | |||
| 2017-12-31 | $12.69M 10-K · filed 2020-03-02 | |||
| 2016-12-31 | $13.58M 10-K · filed 2019-03-01 | |||
| 2015-12-31 | $9.58M 10-K · filed 2018-03-01 | |||
| 2014-12-31 | $8.92M 10-K · filed 2017-03-16 | |||
| 2013-12-31 | $6.25M 10-K · filed 2016-03-15 | |||
| 2012-12-31 | $4.28M 10-K · filed 2015-03-16 | |||
| 2011-12-31 | $1.93M 10-K · filed 2014-03-13 | |||
| 2010-12-31 | $2.18M 10-K · filed 2013-03-18 | |||
| 2009-12-31 | $1.49M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |